Olaparib tablets

DRUG5 trials

Sponsors

AstraZeneca, National Cancer Institute, Naples, Ellipses Pharma

Conditions

BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerGastric CancerOvarian CancerSmall-cell Lung CancerSolid Tumours

Phase 1

To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours

CompletedNCT01921140

AstraZenecaSolid Tumours

Start: 2013-09-24End: 2022-03-15Updated: 2022-11-22

Phase 2

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

National Cancer Institute, NaplesBRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Start: 2019-07-04End: 2023-09-01Target: 200Updated: 2023-03-24

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

CompletedNCT04669002

Ellipses PharmaOvarian Cancer

Start: 2020-12-14End: 2023-05-05Updated: 2023-08-02

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

WithdrawnNCT05411679

Ellipses PharmaGastric Cancer, Small-cell Lung Cancer

Start: 2023-04-30End: 2024-12-31Updated: 2023-06-12

Unknown Phase

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AstraZenecaOvarian Cancer

Updated: 2017-10-25

Related Papers

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.

2016-08-2312 citations